Dogne Jean-Michel
Dogne Jean-Michel
Professor at University of Namur
Verified email at unamur.be
Title
Cited by
Cited by
Year
Impact of dabigatran on a large panel of routine or specific coagulation assays
J Douxfils, F Mullier, S Robert, C Chatelain, B Chatelain, JM Dogné
Thrombosis and haemostasis 107 (05), 985-997, 2012
3862012
Targeting tumor-associated carbonic anhydrase IX in cancer therapy
A Thiry, JM Dogne, B Masereel, CT Supuran
Trends in pharmacological sciences 27 (11), 566-573, 2006
3792006
Adverse cardiovascular effects of the coxibs
JM Dogné, CT Supuran, D Pratico
Journal of medicinal chemistry 48 (7), 2251-2257, 2005
3622005
Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide
J Douxfils, C Chatelain, B Chatelain, JM Dogné, F Mullier
Thrombosis and Haemostasis 110 (08), 283-294, 2013
257*2013
Standardization of pre‐analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop
R Lacroix, C Judicone, M Mooberry, M Boucekine, NS Key, ...
Journal of Thrombosis and Haemostasis 11 (6), 1190-1193, 2013
2402013
Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature
J Douxfils, F Mullier, C Loosen, C Chatelain, B Chatelain, JM Dogné
Thrombosis research 130 (6), 956-966, 2012
2162012
Carbonic anhydrase inhibitors as anticonvulsant agents
A Thiry, JM Dogne, CT Supuran, B Masereel
Current topics in medicinal chemistry 7 (9), 855-864, 2007
1712007
Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation
L Dubois, S Peeters, NG Lieuwes, N Geusens, A Thiry, S Wigfield, F Carta, ...
Radiotherapy and Oncology 99 (3), 424-431, 2011
1632011
Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban
J Douxfils, A Tamigniau, B Chatelain, C Chatelain, P Wallemacq, ...
Thrombosis and haemostasis 110 (10), 723-731, 2013
1442013
Coxibs and cardiovascular side-effects: from light to shadow
JM Dogné, J Hanson, C Supuran, D Pratico
Current pharmaceutical design 12 (8), 971-975, 2006
1432006
Solid lipid microparticles as a sustained release system for pulmonary drug delivery
S Jaspart, P Bertholet, G Piel, JM Dogné, L Delattre, B Evrard
European journal of pharmaceutics and biopharmaceutics 65 (1), 47-56, 2007
1402007
Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis
JM Dogné, J Hanson, D Pratico
Trends in pharmacological sciences 26 (12), 639-644, 2005
1282005
New trends in dual 5-LOX/COX inhibition
X Leval, F Julémont, J Delarge, B Pirotte, JM Dogné
Current medicinal chemistry 9 (9), 941-962, 2002
1162002
Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate
J Douxfils, JM Dogné, F Mullier, B Chatelain, Y Rönquist-Nii, ...
Thrombosis and haemostasis 110 (09), 543-549, 2013
1152013
Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians
J Douxfils, W Ageno, CM Samama, S Lessire, H Ten Cate, P Verhamme, ...
Journal of Thrombosis and Haemostasis 16 (2), 209-219, 2018
1092018
Prostanoids as pharmacological targets in COPD and asthma
S Rolin, B Masereel, JM Dogné
European journal of pharmacology 533 (1-3), 89-100, 2006
1082006
New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators
JM Dogné, X Leval, J Hanson, M Frederich, B Lambermont, A Ghuysen, ...
Current medicinal chemistry 11 (10), 1223-1241, 2004
1032004
New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators
JM Dogné, X Leval, J Hanson, M Frederich, B Lambermont, A Ghuysen, ...
Current medicinal chemistry 11 (10), 1223-1241, 2004
1032004
Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: drug design and mechanism of action
A Thiry, JM Dogne, CT Supuran, B Masereel
Current pharmaceutical design 14 (7), 661-671, 2008
1002008
Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all‐cause mortality: a systematic review and meta‐analysis of …
J Douxfils, F Buckinx, F Mullier, V Minet, V Rabenda, JY Reginster, ...
Journal of the American Heart Association 3 (3), e000515, 2014
992014
The system can't perform the operation now. Try again later.
Articles 1–20